CurrentUnitedHealthcarePolicy CS079TN.T

Minimally Invasive Procedures for Gastric and Esophageal Diseases (for Tennessee Only)

Policy applies to Medicaid and CoverKids in Tennessee and defines medical necessity and noncoverage for minimally invasive endoscopic and laparoscopic procedures for gastric and esophageal diseases (including POEM, G-POEM, endoluminal GERD therapies, FLIP, Z-POEM, LINX). This part includes coverage rationale, definitions, descriptions, evidence summaries, and applicable procedure codes.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for Gastric and Esophageal Diseases (for Tennessee Only)

Policy CodePolicy CS079TN.T

Change TypeCoverage rationale clarified

Effective DateJan 1, 2025

Next Review Date

Key ActionDocument diagnosis of Achalasia or Diffuse Esophageal Spasm to support medical necessity for POEM; other indications require documentation for review.

POLICY UPDATE CHANGES

Clarified that POEM is proven and medically necessary for treating individuals with Achalasia or Diffuse Esophageal Spasm.

Clarified that POEM is unproven and not medically necessary for all other indications (e.g., Zenker's diverticula) due to insufficient evidence of efficacy.

Updated Clinical Evidence and References sections to reflect current information.

2Covered Indications (POEM)

multipleUnproven/Not Medically Necessary

7Procedure codes listed

mixed

limitedLong-term RCT data

Coverage Summary

scope_summary: "Policy applies to Medicaid and CoverKids in Tennessee and defines medical necessity and noncoverage for minimally invasive endoscopic and laparoscopic procedures for gastric and esophageal diseases (including POEM, G-POEM, endoluminal GERD therapies, FLIP, Z-POEM, LINX)." coverage_stance: "mixed" dates.effective: "2025-01-01" policy_number: "CS079TN.T" subject: "Minimally Invasive Procedures for Gastric and Esophageal Diseases (Tennessee)"

Surface key threshold and quick facts

Follow-up duration commentMany studies report short-term follow-up (6–12 months); long-term outcomes beyond 1–5 years are limited

Covered Indications (POEM) value2 (Achalasia and Diffuse Esophageal Spasm)

Unproven indications labelMultiple (POEM for other indications e.g., Zenker's diverticula; G-POEM for gastroparesis; endoscopic/implantation therapies, LINX, FLIP diagnostic use)

Procedure codes listed count7 (codes listed including 43210,43257,43284,43289,43497,43499,43999)

Evidence strength summaryMixed: POEM has strongest supporting evidence (multiple RCTs, systematic reviews; noninferior to LHM), other procedures have limited/low-quality or short-term evidence; many interventions considered investigational or unproven

Medical Necessity Criteria

Medically Necessary (Covered) Procedures

Covered when ALL of the following are met:

ALL of the following

Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with Achalasia.
Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with Diffuse Esophageal Spasm.

Not Medically Necessary / Unproven

The following are considered unproven and not medically necessary:

ANY of the following

POEM for other indications:

Evidence Summaries and Clinical Interpretation

Evidence-based conclusions and coverage implications (narrative)

Summaries of evidence and guideline recommendations used to inform coverage and policy implications:

Transoral incisionless fundoplication (TIF) evidence: Transoral incisionless fundoplication (TIF/EsophyX) shows short-term improvement in symptoms and patient satisfaction versus sham/PPI in some randomized trials, but long-term objective reflux control and sustained PPI discontinuation are limited; randomized trials with longer follow-up are needed.

Polymer injection evidence: Polymer injection/implantation techniques (eg, Plexiglas, Durasphere, Enteryx, Gatekeeper) have insufficient evidence of long-term safety and effectiveness; additional randomized studies are warranted.

LINX evidence: LINX magnetic sphincter augmentation demonstrates short-term symptom improvement and high rates of PPI discontinuation in many series but has limited long-term comparative evidence and concerns about dysphagia, dilation needs, device erosion and removals; further RCTs and longer follow-up are needed.

Applicable Codes and Devices

Applicable Procedure Codes (reference list)mixed

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43999	Unlisted procedure, stomach.

Informational - Devices and Systems discussed (no explicit billing list in this part)mixed

LINX (Torax Medical) PMA P100049	LINX Reflux Management System PMA number referenced (FDA premarket approval March 2012)
Stretta System	Radiofrequency thermal ablation system approved April 2000 (informational)
EsophyX / EsophyX2	EsophyX2 cleared Nov 2009 (510(k)) indicated for TIF, hiatal hernia < 2 cm
MUSE (Medigus Ultrasonic Surgical Endostapler)	510(k) approval Jan 15, 2015 for anterior partial fundoplication
EndoFLIP (Medtronic) K170833	510(k) April 17, 2017; indicated to measure pressure and dimensions as adjunct diagnostic

Provider Actions and Prior Authorization

Documentation Required

Indication documentation for POEM

Document indication for POEM in the medical record: diagnosis (e.g., achalasia subtype or diffuse esophageal spasm), prior objective testing (esophageal manometry, barium swallow, endoscopy), symptom severity, prior non-surgical/endoscopic treatments and responses (e.g., pneumatic dilation, botulinum toxin, medical therapy), and rationale for selecting POEM over alternatives. Include relevant CPT/HCPCS codes when submitted for claims (e.g., 43497).

Required documentation: esophageal manometry report (including achalasia subtype), upper endoscopy report, barium esophagram when available, prior treatment history and dates.
Include operative note describing technique, length and location of myotomy, complications, and disposition.

Documentation Required

Device / therapy FDA status documentation

Document the FDA marketing/clearance status of the specific device or implantable therapy used in the member’s chart and prior authorization submission. For devices without FDA approval/clearance for the intended indication, provide supporting clinical evidence and justification in the medical record.

Definitions

Achalasia: A primary esophageal motor disorder… impaired relaxation of the esophagogastric junction (EGJ) with loss of organized peristalsis.

Diffuse Esophageal Spasm: Rare esophageal motility disorder with simultaneous, uncoordinated, or rapidly propagated contractions accompanied by dysphagia.

Gastroesophageal Reflux Disease: Condition where the lower esophageal sphincter relaxes too often or weakens allowing stomach acid to reflux into the esophagus.

Gastroparesis: Chronic disorder causing delayed stomach emptying without a blockage.

G-POEM: Gastric peroral endoscopic myotomy, an endoscopic pyloromyotomy procedure for refractory gastroparesis.

POEM: Per oral endoscopic myotomy, an endoscopic procedure for myotomy of esophageal muscle layers used to treat achalasia and related motility disorders.

Revision History

2025-01-01Policy changeLatest

Coverage Rationale clarified: POEM is proven and medically necessary for treating individuals with Achalasia or Diffuse Esophageal Spasm; POEM is unproven and not medically necessary for all other indications (e.g., Zenker's diverticula). This change is material and effective 01/01/2025.

2025-01-01AdministrativeLatest

Policy updated: Clinical Evidence and References sections were updated to reflect current information; previous policy version CS079TN.S archived. (Non-material administrative revision.)

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for Gastric and Esophageal Diseases (for Tennessee Only)

Policy CodePolicy CS079TN.T

Change TypeCoverage rationale clarified

Effective DateJan 1, 2025

Next Review Date

Key ActionDocument diagnosis of Achalasia or Diffuse Esophageal Spasm to support medical necessity for POEM; other indications require documentation for review.

On This Page

Per oral endoscopic myotomy (POEM) for all other indications (e.g., Zenker's diverticula) due to insufficient evidence of efficacy.

G-POEM: Gastric peroral endoscopic myotomy (G-POEM) for the treatment of Gastroparesis is unproven and not medically necessary.

Endoscopic GERD therapies: Endoscopic therapies for Gastroesophageal Reflux Disease (GERD) are unproven and not medically necessary due to insufficient evidence of efficacy.

Injection/implantation techniques: Injection or implantation techniques for GERD (eg, polymer injections, bulking agents) are unproven and not medically necessary.

LINX Reflux Management System (magnetic sphincter augmentation) is considered unproven and not medically necessary for routine coverage due to limited long-term comparative evidence and safety concerns.

FLIP: Functional lumen imaging probe (FLIP) technology is unproven and not medically necessary for diagnosing Achalasia.

Endoluminal GERDx: Endoluminal therapy with GERDx™ is investigational, not FDA approved, and not medically necessary for treating GERD.

EndoFLIP evidence: Functional Lumen Imaging Probe (EndoFLIP/FLIP) currently has insufficient evidence to define its utility for diagnosis, procedure guidance, or post-procedure evaluation; thresholds and protocols are not standardized.

Guideline positions: ACG recommends consideration of MSA and conditional use of TIF and recommends against Stretta; AGA recommends POEM for type III achalasia and provides guidance on G-POEM; ASGE suggests endoscopic antireflux therapy may be considered for selected patients; ASGS supports LINX when placed by experienced surgeons.

Minimally invasive endoscopic and laparoscopic procedures are evaluated across a range of gastric and esophageal disorders; evidence quality varies by procedure. The policy identifies POEM as having the strongest and sufficient evidence to be “proven and medically necessary” specifically for Achalasia and Diffuse Esophageal Spasm, based on randomized trials and systematic reviews. Other interventions (for example, G-POEM, endoluminal GERD therapies, FLIP, LINX, and various injection/implantation techniques) are noted to have limited, inconsistent, or low-quality long-term evidence and are classified as unproven or not medically necessary for routine coverage in Tennessee Medicaid/CoverKids. Trials and reviews cited call for additional randomized studies and longer follow-up to define long-term effectiveness and safety for many of these procedures.

Study / Source	Key result
Werner et al. (2019) RCT POEM vs LHM	2‑year clinical success: POEM 83.0% vs LHM 81.7%; noninferiority demonstrated; higher GERD incidence with POEM.
Systematic reviews/meta-analyses (POEM)	POEM clinical success rates generally high (~80–90%); evidence supports POEM as viable first‑line for achalasia/type III with increased reflux risk noted.
G‑POEM outcomes (systematic reviews, pooled analyses)	Symptom scores (GCSI) decreased from ~3.3–3.4 to ~1.8; pooled clinical symptom improvement ~76%; 4‑h GES improved (49.9 to 20.6); evidence limited by heterogeneity and need for larger RCTs.
Martinek et al. (2022) G‑POEM RCT vs sham	G‑POEM: 15/21 successes vs 4/20 sham at 6 months; some serious adverse events related to G‑POEM; limited by small size and short follow‑up.
Stretta RCT (Zerbib 2020)	No significant difference vs sham at 24 and 48 weeks for days without heartburn, PPI use; no procedure‑related safety issues reported in trial.
Stretta meta‑analysis (Fass 2017)	Pooled improvements in HRQL and heartburn scores; about 49% baseline PPI users still required PPIs at follow‑up; evidence low‑moderate quality and longer‑term uncertainty.
TIF / EsophyX outcomes (multiple RCTs/observational)	Short‑term symptom and HRQL improvements and reduced PPI use (eg, TEMPO: high regurgitation elimination up to 5 yrs), but long‑term objective reflux control and sustained PPI discontinuation are limited and variable across studies.
MUSE (Medigus) series	Case series report 64–83% off daily PPI at 6 months, durability variable; serious adverse events (perforations) reported in small numbers.
Endoscopic plication/suturing (EFTP) RCTs/meta‑analyses	RCTs (eg, Kalapala 2022) show superiority to sham for GERD‑HRQL and reduced PPI dependence at 12 months; overall evidence limited and longer‑term trials needed.
Polymer injection / implantation techniques (Plexiglas, Durasphere, Enteryx, Gatekeeper)	Limited small series and systematic reviews conclude insufficient evidence for long‑term safety and effectiveness; progressive loss of benefit over time noted.
MUSE 6‑month and long‑term reports (Zacherl 2015, Kim 2016, Testoni 2022)	Improved GERD‑HRQL and PPI reduction (eg, 64–83% off daily PPI at 6 months; 69% off daily PPI at 4 years in one series); two serious adverse events (perforations) reported.
TIF TEMPO trial (Trad et al. 5‑year) and long‑term TIF reviews	TEMPO: troublesome regurgitation elimination 86% at 5 years; many studies limited by crossover, small size, and loss to follow‑up; objective reflux control wanes over time for some patients.
MSA (LINX) pooled outcomes / systematic reviews	High rates of symptom relief and PPI cessation (many series ~80–88%); dysphagia common (10–29%), dilation and removals reported; erosion rare (~0.3% at 4 years); longer‑term comparative evidence limited.
MSA randomized trials (Bell et al.) and registries	MSA superior to PPIs for regurgitation control in RCTs; prospective series show reduced acid exposure and improved HRQL; need for longer‑term RCTs noted.
EndoFLIP utility and evidence summaries	EndoFLIP (FLIP) has insufficient standardized evidence; distensibility index thresholds and protocols undefined; may predict POEM response but not established for routine diagnosis or guidance.
EndoFLIP pediatric and small studies (Rafeeqi, Yoo)	Shows correlation between DI and symptoms/treatment response in small studies but lacks standardized thresholds and long‑term validation.
Policy change rationale (effective 01/01/2025)	POEM clarified as proven and medically necessary for Achalasia and Diffuse Esophageal Spasm; POEM unproven for other indications (eg, Zenker's) due to insufficient evidence.
Zenker's POEM (Z‑POEM) evidence	Case series and systematic reviews show feasible symptom improvement but evidence limited by small, retrospective studies and insufficient long‑term outcomes; thus insufficient for broader coverage.
G‑POEM systematic reviews/meta‑analyses (Mohan 2020, Stojilkovic 2023, Aziz 2023)	Pooled analyses report clinical success rates and GCSI improvements, but heterogeneity, variable definitions, and limited RCT data limit strength of evidence.
Stretta observational series vs RCT evidence mix	Observational series report long‑term symptom/QOL improvements in some cohorts, but sham‑controlled RCTs found no significant benefit; overall evidence inconsistent.
Polymer injection systematic review (Chen 2009) and case series	Some early positive small studies but overall insufficient evidence to demonstrate durable benefit; off‑label uses noted for many agents.
MSA safety signals (erosion, removals) and large series (Alicuben)	Erosion rare (~0.3% at 4 years); device removals reported (variable rates up to ~9% in cohorts); dysphagia and need for dilation notable adverse events.
EndoFLIP systematic reviews (Desprez, Hayes, ECRI)	Reviews conclude evidence insufficient to define clinical utility across disorders; lack of standardized protocols and thresholds.
Overall narrative and guideline concordance	Guidelines and technology assessments support POEM for achalasia/SED, recommend against or cautious use for Stretta, consider TIF/MSA conditionally; many endoluminal GERD therapies and FLIP remain investigational or unproven for routine coverage.

Examples: LINX Reflux Management System (implantable magnetic sphincter) is an FDA-cleared device for reflux — note model and implant date in documentation.
If using EndoFLIP or other functional lumen imaging devices, state device make/model and whether used for diagnostic support only; EndoFLIP is considered unproven for diagnosing achalasia per this policy — document how results influenced management.

Prior Authorization

Policy-based coverage determination

Prior authorization and contractual coverage determination is required per applicable Tennessee Medicaid/CoverKids rules for procedures subject to medical necessity review. Submit full clinical records to support medical necessity.

Include all relevant diagnostic test reports, prior conservative management, and rationale tied to policy criteria.
Ensure CPT codes (e.g., 43497) and ICD-10 diagnosis codes are listed on the prior authorization request.
If the device is implantable (e.g., LINX), include device model and FDA status in the prior authorization submission.

Documentation Required

Patient selection and counseling for TIF and MSA

Use guideline- and evidence-based patient selection and counseling; document discussion of risks, benefits, alternatives (including medical therapy, pneumatic dilation, laparoscopic Heller myotomy, and fundoplication when applicable), and expected outcomes. For TIF and MSA candidate selection, document objective testing and PPI response.

Document documented poor response or intolerance to optimal PPI therapy when considering antireflux procedures.
Confirm endoscopic findings (e.g., hiatal hernia size) and anatomical suitability for TIF or MSA; include endoscopy or imaging reports in the record.

Documentation Required

Confirm objective testing prior to MSA

Confirm and document objective testing prior to magnetic sphincter augmentation (MSA): esophageal motility testing (high-resolution manometry) and other studies as indicated to exclude significant motility disorders that would contraindicate MSA.

Required tests: high-resolution esophageal manometry report, upper endoscopy findings, and barium esophagram when indicated.
If EndoFLIP is used adjunctively, document how FLIP results correlated with manometry and influenced the decision to proceed.

Documentation Required

EndoFLIP use

Document use of EndoFLIP (functional lumen imaging probe) when utilized: device make/model, measurement parameters, procedural details, and how the results affected clinical decision-making. Note that EndoFLIP is considered unproven for diagnosing achalasia in this policy; when used, it should be adjunctive to standard diagnostic tests.

Record numeric FLIP metrics (e.g., distensibility index) and interpretation relative to concurrent manometry findings.
State explicitly in notes that EndoFLIP alone is insufficient for diagnosis of achalasia per policy; include supporting manometry and imaging reports.

Documentation Required

Use clinical evidence and guideline-based selection

Use clinical evidence and guideline-based selection for all procedures; document adherence to guideline criteria and cite relevant guideline-based indications in the chart. If deviating from guidelines, document the clinical rationale.

When billing, include appropriate CPT codes (e.g., 43497 for POEM) and link to documented indications.
For investigational or unproven procedures (e.g., Endoluminal therapies not FDA-approved for GERD, G-POEM for gastroparesis), clearly note investigational status and include informed consent discussion in the record.